Kamada Ltd Company Profile (NASDAQ:KMDA)

About Kamada Ltd

Kamada Ltd logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KMDA
  • CUSIP:
Key Metrics:
  • Previous Close: $7.20
  • 50 Day Moving Average: $6.472
  • 200 Day Moving Average: $5.539
  • 52-Week Range: $3.47 - $7.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 10.43
  • P/E Growth: -118.330
  • Market Cap: $262.24M
  • Outstanding Shares: 36,447,000
  • Beta: 1.02
Profitability:
  • Net Margins: -8.69%
  • Return on Equity: -9.77%
  • Return on Assets: -6.74%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 2.83%
  • Quick Ratio: 1.89%
Additional Links:
Companies Related to Kamada Ltd:

Analyst Ratings

Consensus Ratings for Kamada Ltd (NASDAQ:KMDA) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.50 (18.14% upside)

Analysts' Ratings History for Kamada Ltd (NASDAQ:KMDA)
Show:
DateFirmActionRatingPrice TargetDetails
2/7/2017HC WainwrightSet Price TargetBuy$10.00View Rating Details
11/11/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Kamada Ltd (NASDAQ:KMDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/201712/31/2016$0.01($0.05)ViewListenView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05ViewN/AView Earnings Details
11/13/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kamada Ltd (NASDAQ:KMDA)
Current Year EPS Consensus Estimate: $-0.010 EPS
Next Year EPS Consensus Estimate: $0.690 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.11)($0.11)($0.11)
Q2 20161($0.04)($0.04)($0.04)
Q3 20161($0.01)($0.01)($0.01)
Q4 20161$0.01$0.01$0.01
Q1 20171$0.00$0.00$0.00
Q2 20171$0.01$0.01$0.01
Q3 20171$0.03$0.03$0.03
Q4 20171$0.07$0.07$0.07
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kamada Ltd (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kamada Ltd (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Kamada Ltd (NASDAQ:KMDA)
DateHeadline
News IconKamada Ltd. (NASDAQ:KMDA) Valuation According To Analysts - UK Market News (NASDAQ:KMDA)
www.ukmarketnews.co.uk - February 23 at 6:09 PM
streetinsider.com logoKamada (KMDA) to Collaborate with MGH on Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver ... - StreetInsider.com (NASDAQ:KMDA)
www.streetinsider.com - February 22 at 6:22 PM
streetinsider.com logoKamada (KMDA) to Collaborate with MGH on Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation (NASDAQ:KMDA)
www.streetinsider.com - February 22 at 12:25 PM
us.rd.yahoo.com logoKamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation (NASDAQ:KMDA)
us.rd.yahoo.com - February 22 at 12:25 PM
us.rd.yahoo.com logo6:33 am Kamada announces a collaboration w/ Massachusetts General Hospital to conduct a study evaluating the potential benefit of its Liquid Alpha-1 Antitrypsin on liver preservation (NASDAQ:KMDA)
us.rd.yahoo.com - February 22 at 12:25 PM
capitalcube.com logoKamada Ltd. :KMDA-US: Earnings Analysis: 2016 By the Numbers : February 9, 2017 (NASDAQ:KMDA)
www.capitalcube.com - February 9 at 7:06 PM
finance.yahoo.com logoKamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors (NASDAQ:KMDA)
finance.yahoo.com - February 8 at 6:56 PM
globenewswire.com logoKamada Reports Financial Results for the Fourth Quarter and Full-Year 2016 (NASDAQ:KMDA)
globenewswire.com - February 6 at 10:21 AM
sg.finance.yahoo.com logoKamada reports 4Q loss (NASDAQ:KMDA)
sg.finance.yahoo.com - February 6 at 10:21 AM
News IconCould Kamada Ltd (KMDA) Lose its Strength? The Stock Reaches 52-Week High (NASDAQ:KMDA)
randolphguide.com - February 3 at 6:51 PM
finance.yahoo.com logoKamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6 (NASDAQ:KMDA)
finance.yahoo.com - February 1 at 6:58 PM
News IconWhat’s Kamada Ltd (KMDA) Upside After Forming Double Top? (NASDAQ:KMDA)
randolphguide.com - January 30 at 6:50 PM
globenewswire.com logoKamada Announces Positive Scientific Advice Response from the European ... (NASDAQ:KMDA)
globenewswire.com - January 23 at 10:37 AM
streetinsider.com logoKamada (KMDA) Announces Positive Scientific Advice Response from CHMP on G1-AAT IV for aGvHD (NASDAQ:KMDA)
www.streetinsider.com - January 23 at 10:37 AM
finance.yahoo.com logo6:30 am Kamada announces positive scientific advice response from the EMA focused on Alpha-1 Antitrypsin IV for treatment of acute graft-versus-host disease; co is in the process of reviewing CHMP guidance (NASDAQ:KMDA)
finance.yahoo.com - January 23 at 10:37 AM
finance.yahoo.com logoKamada Announces Positive Scientific Advice Response from the European Medicines Agency Focused on Alpha-1 Antitrypsin IV for Treatment of Acute Graft-Versus-Host Disease (NASDAQ:KMDA)
finance.yahoo.com - January 23 at 10:37 AM
capitalcube.com logoETFs with exposure to Kamada Ltd. : January 20, 2017 (NASDAQ:KMDA)
www.capitalcube.com - January 20 at 4:24 PM
News IconKamada Ltd KMDA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:KMDA)
www.bioportfolio.com - January 7 at 8:23 PM
capitalcube.com logoETFs with exposure to Kamada Ltd. : December 14, 2016 (NASDAQ:KMDA)
www.capitalcube.com - December 14 at 6:49 PM
capitalcube.com logoETFs with exposure to Kamada Ltd. : December 2, 2016 (NASDAQ:KMDA)
www.capitalcube.com - December 2 at 5:55 PM
capitalcube.com logoKamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:KMDA)
www.capitalcube.com - November 29 at 4:19 PM
News IconKamada Ltd. KMDA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:KMDA)
www.bioportfolio.com - November 24 at 5:55 PM
News IconKamada Ltd. KMDA Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:KMDA)
www.bioportfolio.com - November 22 at 9:52 AM
News IconKamada Ltd. Announces Collaboration Agreement With Yissum Ltd. For Development Of A Recombinant Human Alpha 1 Antitrypsin (NASDAQ:KMDA)
www.biospace.com - November 15 at 6:25 PM
streetinsider.com logoKamada (KMDA) Enters Recombinant Human Alpha 1 Antitrypsin Development Agreement (NASDAQ:KMDA)
www.streetinsider.com - November 15 at 6:25 PM
finance.yahoo.com logoKamada Announces Collaboration Agreement with Yissum for Development of a Recombinant Human Alpha 1 Antitrypsin (NASDAQ:KMDA)
finance.yahoo.com - November 15 at 9:28 AM
finance.yahoo.com logoCan Agilent Technologies (A) Pull a Surprise in Q4 Earnings? (NASDAQ:KMDA)
finance.yahoo.com - November 14 at 9:54 AM
sg.finance.yahoo.com logoKamada reports 3Q loss (NASDAQ:KMDA)
sg.finance.yahoo.com - November 10 at 5:21 PM
publicnow.com logoKamada Reports Financial Results for the Third Quarter and Nine Months of 2016 (NASDAQ:KMDA)
www.publicnow.com - November 10 at 8:27 AM
streetinsider.com logoKamada (KMDA), Kedrion Biopharma Announce FDA Acceptance of IgG Therapy BLA (NASDAQ:KMDA)
www.streetinsider.com - November 8 at 8:47 AM
seekingalpha.com logoFDA accepts Kamada's marketing application for rabies IgG therapy; action date August 29, 2017 (NASDAQ:KMDA)
seekingalpha.com - November 7 at 9:40 AM
finance.yahoo.com logoKedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment (NASDAQ:KMDA)
finance.yahoo.com - November 7 at 9:40 AM
finance.yahoo.com logoKamada to Host Third Quarter Financial Results Conference Call on November 10, 2016 at 8:30 am Eastern Time (NASDAQ:KMDA)
finance.yahoo.com - November 3 at 9:34 AM
publicnow.com logoKamada Announces Plan for Phase 2/3 Clinical Trial with Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease (NASDAQ:KMDA)
www.publicnow.com - November 2 at 9:21 AM
finance.yahoo.com logoKamada (KMDA) Extends Partnership with Shire for Glassia (NASDAQ:KMDA)
finance.yahoo.com - October 10 at 10:30 AM
News IconKamada extends Shire Glassia agreement (NASDAQ:KMDA)
www.globes.co.il - October 6 at 5:42 PM
nasdaq.com logoExtended Agreement May Expand to $288 Million of Revenue in 2017 to 2020 (NASDAQ:KMDA)
www.nasdaq.com - October 6 at 5:42 PM
seekingalpha.com logoKamada and Shire extend Glassia supply agreement through 2020 (NASDAQ:KMDA)
seekingalpha.com - October 6 at 5:42 PM
streetinsider.com logoKamada (KMDA), Shire (SHPG) Extend GLASSIA Supply and Distribution Agreement (NASDAQ:KMDA)
www.streetinsider.com - October 6 at 5:42 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Kamada (NASDAQ:KMDA)
finance.yahoo.com - September 12 at 5:38 PM
finance.yahoo.com logoKamada to Present a Corporate Overview at the Rodman & Renshaw 18th Annual Investment Conference (NASDAQ:KMDA)
finance.yahoo.com - September 9 at 10:35 AM
thestreet.com logo4 Biotechs Set to Provide a Shot in the Arm (NASDAQ:KMDA)
realmoney.thestreet.com - September 9 at 10:35 AM
benzinga.com logoH.C. Wainwright Talks Kamada's Recent Phase 2 Results (NASDAQ:KMDA)
www.benzinga.com - September 1 at 5:42 PM
seekingalpha.com logoMarketing application filed in U.S. for Kamada's post-exposure rabies therapy; launch planned in 2017 (NASDAQ:KMDA)
seekingalpha.com - September 1 at 8:54 AM
publicnow.com logoKamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment (NASDAQ:KMDA)
www.publicnow.com - September 1 at 8:54 AM
News IconKamada succeeds in phase 2 inhaled drug trial (NASDAQ:KMDA)
www.globes.co.il - August 31 at 10:40 AM
streetinsider.com logoKamada (KMDA): Phase II Trial Adds Support For Inhaled AAT Therapy - Jefferies (NASDAQ:KMDA)
www.streetinsider.com - August 31 at 10:40 AM
nasdaq.com logoKamada's Phase 2 Trial Of Alpha-1 Antitrypsin Therapy Meets Primary Endpoint (NASDAQ:KMDA)
www.nasdaq.com - August 30 at 9:06 AM
seekingalpha.com logoMid-stage study of Kamada's inhaled AAT therapy in AATD successful; shares up 7% premarket (NASDAQ:KMDA)
seekingalpha.com - August 30 at 9:06 AM
streetinsider.com logoKamada's (KMDA) Inhaled Alpha-1 Antitrypsin Phase 2 Met Primary Endpoint (NASDAQ:KMDA)
www.streetinsider.com - August 30 at 9:06 AM

Social

What is Kamada Ltd's stock symbol?

Kamada Ltd trades on the NASDAQ under the ticker symbol "KMDA."

Where is Kamada Ltd's stock going? Where will Kamada Ltd's stock price be in 2017?

2 analysts have issued twelve-month target prices for Kamada Ltd's shares. Their forecasts range from $7.00 to $10.00. On average, they expect Kamada Ltd's stock price to reach $8.50 in the next twelve months.

Who owns Kamada Ltd stock?

Kamada Ltd's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Provident funds of MEITAV DASH INVESTMENTS LTD group (7.00%), Paulson & CO. Inc. (2.01%), Renaissance Technologies LLC (0.62%), Menora Mivtachim Holdings LTD. (0.26%) and Analyst IMS Investment Management Services Ltd. (0.11%).

Who bought Kamada Ltd stock? Who is buying Kamada Ltd stock?

Kamada Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Paulson & CO. Inc. and Renaissance Technologies LLC.

How do I buy Kamada Ltd stock?

Shares of Kamada Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kamada Ltd stock cost?

One share of Kamada Ltd stock can currently be purchased for approximately $7.20.

Kamada Ltd (NASDAQ:KMDA) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Kamada Ltd (NASDAQ:KMDA)

Earnings History Chart

Earnings by Quarter for Kamada Ltd (NASDAQ:KMDA)

Dividend History Chart

Dividend Payments by Quarter for Kamada Ltd (NASDAQ:KMDA)

Last Updated on 2/25/2017 by MarketBeat.com Staff